gadopentetate dimeglumine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4558	80529-93-7

Description:

Molecule	Description
Synonyms: magnevist gadopentetic acid Gd-DTPA gadopentetate dimeglumine	A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) Molecular weight: 545.56 Formula: C14H18GdN3O10 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

magnevist
gadopentetic acid
Gd-DTPA
gadopentetate dimeglumine

A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)

Molecular weight: 545.56
Formula: C14H18GdN3O10
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 2, 1988	FDA	BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	1374.17	39.62	268	8033	4288	63476433
Urticaria	1133.79	39.62	509	7792	165293	63315428
Skin induration	486.57	39.62	107	8194	3116	63477605
Skin hypertrophy	448.33	39.62	101	8200	3290	63477431
Pruritus	424.23	39.62	360	7941	361093	63119628
Skin tightness	317.28	39.62	80	8221	4236	63476485
Sneezing	314.67	39.62	110	8191	18108	63462613
Throat irritation	228.01	39.62	107	8194	37540	63443181
Erythema	227.55	39.62	186	8115	175565	63305156
Skin fibrosis	223.84	39.62	45	8256	835	63479886
Fibrosis	213.13	39.62	58	8243	4134	63476587
Joint contracture	162.30	39.62	39	8262	1685	63479036
Contrast media reaction	162.23	39.62	36	8265	1089	63479632
Throat tightness	160.75	39.62	74	8227	24813	63455908
Skin hyperpigmentation	155.16	39.62	49	8252	5872	63474849
Vomiting	137.29	39.62	254	8047	559363	62921358
Scar	128.18	39.62	53	8248	13729	63466992
Drug ineffective	123.23	39.62	3	8298	1044762	62435959
Joint range of motion decreased	122.41	39.62	67	8234	32361	63448360
Skin discolouration	118.05	39.62	69	8232	37759	63442962
Dyspnoea	98.18	39.62	245	8056	661068	62819653
Anhedonia	97.98	39.62	41	8260	10933	63469788
Emotional distress	97.94	39.62	58	8243	32491	63448230
Nausea	90.72	39.62	280	8021	854191	62626530
Oedema peripheral	88.34	39.62	116	8185	189395	63291326
Eye swelling	86.34	39.62	48	8253	23870	63456851
Skin plaque	84.19	39.62	34	8267	8286	63472435
Feeling hot	77.13	39.62	59	8242	50295	63430426
Extremity contracture	75.78	39.62	20	8281	1265	63479456
Rash macular	73.86	39.62	43	8258	23321	63457400
Peau d'orange	71.49	39.62	13	8288	137	63480584
Joint stiffness	68.42	39.62	51	8250	41818	63438903
Chest discomfort	66.83	39.62	77	8224	109892	63370829
Nasal congestion	65.41	39.62	60	8241	65600	63415121
Deformity	60.90	39.62	30	8271	11654	63469067
Contrast media deposition	60.57	39.62	10	8291	56	63480665
Off label use	59.03	39.62	9	8292	674453	62806268
Mobility decreased	56.11	39.62	74	8227	121085	63359636
Swollen tongue	55.98	39.62	42	8259	34758	63445963
Choking sensation	55.73	39.62	20	8281	3534	63477187
Muscle contracture	55.60	39.62	16	8285	1395	63479326
Burning sensation	54.73	39.62	50	8251	54357	63426364
Diarrhoea	51.45	39.62	15	8286	715351	62765370
Contrast media allergy	47.23	39.62	16	8285	2385	63478336
Skin disorder	46.10	39.62	35	8266	29472	63451249
Hypoaesthesia oral	43.88	39.62	25	8276	13008	63467713
Muscle tightness	43.25	39.62	24	8277	11876	63468845
Anaphylactic reaction	43.03	39.62	48	8253	66052	63414669
Flushing	42.95	39.62	51	8250	75036	63405685
Oral pruritus	40.14	39.62	14	8287	2277	63478444

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	1227.88	46.11	247	5391	3758	34947535
Skin induration	450.62	46.11	97	5541	2054	34949239
Urticaria	423.38	46.11	204	5434	62173	34889120
Skin hypertrophy	366.62	46.11	85	5553	2544	34948749
Skin tightness	357.89	46.11	81	5557	2172	34949121
Sneezing	299.15	46.11	83	5555	5159	34946134
Skin fibrosis	246.12	46.11	52	5586	1000	34950293
Joint contracture	239.67	46.11	57	5581	1904	34949389
Joint range of motion decreased	233.95	46.11	74	5564	7238	34944055
Pruritus	201.76	46.11	173	5465	141808	34809485
Scar	189.46	46.11	60	5578	5884	34945409
Vomiting	182.80	46.11	211	5427	247410	34703883
Fibrosis	176.58	46.11	47	5591	2489	34948804
Extremity contracture	150.35	46.11	33	5605	763	34950530
Deformity	137.83	46.11	35	5603	1537	34949756
Emotional distress	132.06	46.11	59	5579	14967	34936326
Mobility decreased	121.97	46.11	70	5568	30058	34921235
Nausea	112.94	46.11	198	5440	339710	34611583
Erythema	111.30	46.11	101	5537	88679	34862614
Anhedonia	107.89	46.11	42	5596	7543	34943750
Joint stiffness	93.29	46.11	42	5596	10831	34940462
Contrast media reaction	92.56	46.11	23	5615	923	34950370
Skin hyperpigmentation	87.86	46.11	29	5609	3235	34948058
Skin discolouration	87.32	46.11	47	5591	17798	34933495
Injury	83.50	46.11	48	5590	20639	34930654
Oedema peripheral	71.36	46.11	92	5546	119720	34831573
Pain	67.27	46.11	119	5519	204556	34746737
Skin disorder	67.14	46.11	36	5602	13519	34937774
Nasal congestion	66.11	46.11	43	5595	23014	34928279
Eye swelling	65.32	46.11	32	5606	9963	34941330
Musculoskeletal stiffness	62.10	46.11	55	5583	46625	34904668
Burning sensation	56.92	46.11	36	5602	18358	34932935
Peau d'orange	56.21	46.11	11	5627	141	34951152
Throat tightness	55.33	46.11	27	5611	8331	34942962
Drug ineffective	53.03	46.11	6	5632	456745	34494548
Anxiety	52.45	46.11	72	5566	99356	34851937
Death	52.34	46.11	3	5635	398046	34553247
Hypoaesthesia	51.08	46.11	56	5582	61388	34889905
Muscle contracture	49.94	46.11	15	5623	1229	34950064
Skin plaque	49.92	46.11	21	5617	4593	34946700
Anaphylactic reaction	46.85	46.11	40	5598	32261	34919032

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	1794.33	48.05	360	11585	5800	79726643
Urticaria	1364.73	48.05	625	11320	184576	79547867
Skin induration	721.48	48.05	161	11784	4364	79728079
Skin hypertrophy	648.81	48.05	150	11795	4778	79727665
Pruritus	562.31	48.05	466	11479	394182	79338261
Skin tightness	549.31	48.05	134	11811	5388	79727055
Sneezing	543.81	48.05	175	11770	19508	79712935
Skin fibrosis	348.49	48.05	73	11872	1451	79730992
Joint contracture	301.30	48.05	71	11874	2453	79729990
Erythema	294.41	48.05	253	11692	223037	79509406
Vomiting	274.87	48.05	411	11534	665417	79067026
Fibrosis	267.02	48.05	75	11870	5234	79727209
Joint range of motion decreased	251.41	48.05	115	11830	33167	79699276
Scar	225.28	48.05	85	11860	15111	79717332
Throat irritation	222.86	48.05	113	11832	40833	79691610
Contrast media reaction	214.78	48.05	52	11893	2018	79730425
Skin hyperpigmentation	201.77	48.05	65	11880	7238	79725205
Nausea	180.25	48.05	422	11523	956774	78775669
Throat tightness	178.52	48.05	86	11859	27821	79704622
Skin discolouration	171.59	48.05	95	11850	40939	79691504
Extremity contracture	146.84	48.05	37	11908	1695	79730748
Emotional distress	141.46	48.05	83	11862	39886	79692557
Eye swelling	140.90	48.05	72	11873	26396	79706047
Anhedonia	139.87	48.05	60	11885	14838	79717605
Dyspnoea	134.59	48.05	353	11592	856672	78875771
Drug ineffective	130.85	48.05	8	11937	1080905	78651538
Joint stiffness	129.46	48.05	79	11866	40751	79691692
Oedema peripheral	127.21	48.05	172	11773	252116	79480327
Deformity	125.41	48.05	49	11896	9556	79722887
Off label use	118.52	48.05	4	11941	907211	78825232
Mobility decreased	109.56	48.05	112	11833	122063	79610380
Peau d'orange	105.22	48.05	21	11924	324	79732119
Nasal congestion	105.10	48.05	89	11856	76463	79655980
Skin plaque	103.25	48.05	44	11901	10701	79721742
Feeling hot	102.22	48.05	79	11866	59655	79672788
Burning sensation	101.33	48.05	78	11867	58554	79673889
Skin disorder	95.78	48.05	61	11884	33882	79698561
Anaphylactic reaction	88.49	48.05	84	11861	83659	79648784
Muscle contracture	82.30	48.05	25	11920	2292	79730151
Rash macular	81.69	48.05	52	11893	28847	79703596
Diarrhoea	80.62	48.05	17	11928	880472	78851971
Pneumonia	79.35	48.05	5	11940	660241	79072202
Flushing	75.62	48.05	79	11866	88189	79644254
Contrast media allergy	71.91	48.05	23	11922	2499	79729944
Muscle tightness	71.24	48.05	36	11909	12878	79719565
Chest discomfort	67.73	48.05	93	11852	137951	79594492
Contrast media deposition	67.33	48.05	12	11933	96	79732347
Pharyngeal oedema	60.74	48.05	35	11910	16237	79716206
Death	60.65	48.05	7	11938	566507	79165936
Swelling face	59.67	48.05	63	11882	71149	79661294
Injury	58.70	48.05	65	11880	77431	79655012
Anxiety	57.98	48.05	120	11825	248392	79484051
Hypoaesthesia	55.90	48.05	98	11847	179254	79553189
Ocular hyperaemia	54.19	48.05	40	11905	28166	79704277
Musculoskeletal stiffness	52.44	48.05	94	11851	174914	79557529
Choking sensation	51.24	48.05	20	11925	3886	79728557
Pain of skin	50.76	48.05	30	11915	14583	79717860
Skin exfoliation	50.21	48.05	51	11894	55049	79677394
Anaemia	48.87	48.05	5	11940	445010	79287433

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08CA01	VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media
FDA MoA	N0000175862	Magnetic Resonance Contrast Activity
FDA EPC	N0000180184	Paramagnetic Contrast Agent
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01707	KEGG_DRUG
4019578	VUID
N0000179141	NUI
4019578	VANDF
CHEBI:31797	CHEBI
CHEMBL1200431	ChEMBL_ID
RH248G8V27	UNII
DB00789	DRUGBANK_ID
25486	RXNORM
4772	MMSL
6030	MMSL
d01451	MMSL
000676	NDDF
004527	NDDF
710811005	SNOMEDCT_US
C0060934	UMLSCUI
D019786	MESH_DESCRIPTOR_UI
5396	INN_ID
86050-77-3	SECONDARY_CAS_RN
55466	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Magnevist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-188	INJECTION	469.01 mg	INTRAVENOUS	NDA	28 sections
Magnevist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-188	INJECTION	469.01 mg	INTRAVENOUS	NDA	28 sections